R&D
Alzheimer's research is moving toward more selective targets
As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.
Market Access
How new PBM transparency rules will alter drug pricing
The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.
Market Access
Sponsored
From first approval to lasting value: What sets successful e...
Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Market Access
Request to look further into NICE non-submissions in the fut...
Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.
R&D
Changing Faces: Board of Director and Advisory Board hires, ...
Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
